Moderna: Taiwan FDA approves new Covid vaccine
(CercleFinance.com) - Moderna today announced that Taiwan's Food & Drug Administration has approved an updated formulation of the COVID-19 mRNA vaccine, Spikevax, targeting the JN.
1 variant, in people aged six months and over.
In April 2024, the World Health Organization (WHO) Technical Advisory Group on COVID-19 Vaccine Composition (TAG-CO-VAC) issued guidelines recommending the use of a monovalent JN.1 for the antigenic composition of COVID-19 vaccines.
Regulatory submissions for Moderna's updated vaccine are currently under review by regulatory agencies worldwide, with decisions expected in the coming weeks, the laboratory says.
Copyright (c) 2024 CercleFinance.com. All rights reserved.
1 variant, in people aged six months and over.
In April 2024, the World Health Organization (WHO) Technical Advisory Group on COVID-19 Vaccine Composition (TAG-CO-VAC) issued guidelines recommending the use of a monovalent JN.1 for the antigenic composition of COVID-19 vaccines.
Regulatory submissions for Moderna's updated vaccine are currently under review by regulatory agencies worldwide, with decisions expected in the coming weeks, the laboratory says.
Copyright (c) 2024 CercleFinance.com. All rights reserved.